TY  - JOUR
AU  - Vekić, Jelena
AU  - Vujčić, Sanja
AU  - Bufan, Biljana
AU  - Bojanin, Dragana
AU  - Al-Hashmi, Khamis
AU  - Al-Rasadi, Khaild
AU  - Stoian, Anca Pantea
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4415
AB  - Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
PB  - MDPI
T2  - Metabolites
T1  - The Role of Advanced Glycation End Products on Dyslipidemia
VL  - 13
IS  - 1
DO  - 10.3390/metabo13010077
ER  - 

@article{
author = "Vekić, Jelena and Vujčić, Sanja and Bufan, Biljana and Bojanin, Dragana and Al-Hashmi, Khamis and Al-Rasadi, Khaild and Stoian, Anca Pantea and Zeljković, Aleksandra and Rizzo, Manfredi",
year = "2023",
abstract = "Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.",
publisher = "MDPI",
journal = "Metabolites",
title = "The Role of Advanced Glycation End Products on Dyslipidemia",
volume = "13",
number = "1",
doi = "10.3390/metabo13010077"
}

Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A. P., Zeljković, A.,& Rizzo, M.. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites
MDPI., 13(1).
https://doi.org/10.3390/metabo13010077

Vekić J, Vujčić S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljković A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites. 2023;13(1).
doi:10.3390/metabo13010077 .

Vekić, Jelena, Vujčić, Sanja, Bufan, Biljana, Bojanin, Dragana, Al-Hashmi, Khamis, Al-Rasadi, Khaild, Stoian, Anca Pantea, Zeljković, Aleksandra, Rizzo, Manfredi, "The Role of Advanced Glycation End Products on Dyslipidemia" in Metabolites, 13, no. 1 (2023),
https://doi.org/10.3390/metabo13010077 . .